APTX News and Press, Aptinyx Inc. From 09/20/21

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Canto...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV)....

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23 rd Annual Global Investment Conference to be held...

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q2 2021 Earnings Call Aug 10, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q2 2021 Earnings Call Transcript

Aptinyx Inc. (APTX) Q2 2021 Earnings Conference Call August 10, 2021, 17:00 PM ET Company Participants Nick Smith - Vice President, Corporate Development & IR Norbert Riedel - Chief Executive Officer Andy Kidd - President & Chief Operating Officer Ashish Khanna - Chief Financial Offic...

Enrollment on track in both Phase 2b chronic pain studies with NYX-2925 — data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study with NYX-458—data readout expected 2H 2022 Completed FDA meeting on NYX-783 development&...

Enrollment on track in both Phase 2b chronic pain studies with NYX-2925 — data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study with NYX-458—data readout expected 2H 2022 Completed FDA meeting on NYX-783 development&...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report ...

APTX stock went into long-term depression following a failed trial in 2019. However, the company has continued progressing its oral NMDA receptor modulator in the same indication, in a subgroup. The company has a decent amount of cash. For further details see: Aptinyx: C...